Prevention of Peripheral Tolerance by a Dendritic Cell Growth Factor: Flt3 Ligand as an Adjuvant

Injections of soluble proteins are poorly immunogenic, and often elicit antigen-specific tolerance. The mechanism of this phenomenon has been an enduring puzzle, but it has been speculated that tolerance induction may be due to antigen presentation by poorly stimulatory, resting B cells, which lack specific immunoglobulin receptors for the protein. In contrast, adjuvants, or infectious agents, which cause the release of proinflammatory cytokines such as tumor necrosis factor α and interleukin 1β in vivo are believed to recruit and activate professional antigen-presenting cells to the site(s) of infection, thereby eliciting immunity. Here we show that administration of Flt3 ligand (FL), a cytokine capable of inducing large numbers of dendritic cells (DCs) in vivo, (a) dramatically enhances the sensitivity of antigen-specific B and T cell responses to systemic injection of a soluble protein, through a CD40–CD40 ligand–dependent mechanism; (b) influences the class of antibody produced; and (c) enables productive immune responses to otherwise tolerogenic protocols. These data support the hypothesis that the delicate balance between immunity and tolerance in vivo is pivotally controlled by DCs, and underscore the potential of FL as a vaccine adjuvant for immunotherapy in infectious disease and other clinical settings.

[1]  A. Mowat,et al.  Expanding dendritic cells in vivo enhances the induction of oral tolerance. , 1998, Journal of immunology.

[2]  D. Kufe,et al.  Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Abbas,et al.  Homeostasis and self-tolerance in the immune system: turning lymphocytes off. , 1998, Science.

[4]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[5]  A. Khoruts,et al.  A Natural Immunological Adjuvant Enhances T Cell Clonal Expansion through a CD28-dependent, Interleukin (IL)-2–independent Mechanism , 1998, The Journal of experimental medicine.

[6]  A. Demetris,et al.  Augmentation of dendritic cells in murine organ donors by Flt3 ligand alters the balance between transplant tolerance and immunity. , 1997, Journal of immunology.

[7]  B. Pulendran,et al.  Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. , 1997, Journal of immunology.

[8]  R. Germain,et al.  Antigen-unspecific B Cells and Lymphoid Dendritic Cells Both Show Extensive Surface Expression of Processed Antigen–Major Histocompatibility Complex Class II Complexes after Soluble Protein Exposure In Vivo or In Vitro , 1997, The Journal of experimental medicine.

[9]  A. Khoruts,et al.  Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. , 1997, Journal of immunology.

[10]  Robert E. Miller,et al.  Flt3 ligand induces tumor regression and antitumor immune responses in vivo , 1997, Nature Medicine.

[11]  T. Strom,et al.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. , 1997, Immunity.

[12]  E. Maraskovsky,et al.  Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified , 1996, The Journal of experimental medicine.

[13]  J. Suttles,et al.  The many roles of CD40 in cell-mediated inflammatory responses. , 1996, Immunology today.

[14]  R. Flavell,et al.  A central role of CD40 ligand in the regulation of CD4+ T-cell responses. , 1996, Immunology today.

[15]  N. Romani,et al.  High Level IL-12 Product ion by Murine Dendrit ic Cells : Upregulation via MHC Class II and CD 40 Molecules and Downregulat ion by IL-4 and IL-10 By , 2003 .

[16]  A. Lanzavecchia,et al.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.

[17]  F. Alt,et al.  CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Steinman,et al.  The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro , 1994, The Journal of experimental medicine.

[19]  R J Armitage,et al.  Humoral immune responses in CD40 ligand-deficient mice , 1994, The Journal of experimental medicine.

[20]  R. Flavell,et al.  Mice deficient for the CD40 ligand. , 1994, Immunity.

[21]  D. Loh,et al.  Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. , 1994, Immunity.

[22]  N. Yoshida,et al.  The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. , 1994, Immunity.

[23]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[24]  H. Burstein,et al.  In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen , 1993, The Journal of experimental medicine.

[25]  P. Matzinger,et al.  B cells turn off virgin but not memory T cells. , 1992, Science.

[26]  P. Morrissey,et al.  Beta 2-microglobulin-, CD8+ T-cell-deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Parker,et al.  Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens , 1992, The Journal of experimental medicine.

[28]  C. Janeway,et al.  Microbial induction of co-stimulatory activity for CD4 T-cell growth. , 1991, International immunology.

[29]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.

[30]  A. Heimberger,et al.  Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. , 1990, Science.

[31]  H. Weiner,et al.  Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. III. Synergistic effect of lipopolysaccharide. , 1990 .

[32]  R. Schwartz,et al.  A cell culture model for T lymphocyte clonal anergy. , 1990, Science.

[33]  C. Whitacre,et al.  Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. , 1988, Cellular immunology.

[34]  L. Chedid,et al.  Current status of immunological adjuvants. , 1986, Annual review of immunology.

[35]  P. Marrack,et al.  The major histocompatibility complex-restricted antigen receptor on T cells. , 1984, Annual review of immunology.

[36]  P. Marrack,et al.  The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody , 1983, The Journal of experimental medicine.

[37]  G. Nossal.  Cellular mechanisms of immunologic tolerance. , 1983, Annual review of immunology.

[38]  D. E. Parks,et al.  Bacterial lipopolysaccharide (endotoxin) interferes with the induction of tolerance and primes thymus-derived lymphocytes. , 1981, Journal of immunology.

[39]  F. Burnet.  A modification of jerne's theory of antibody production using the concept of clonal selection , 1976, CA: a cancer journal for clinicians.

[40]  G. Habicht,et al.  Kinetic Differences in Unresponsiveness of Thymus and Bone Marrow Cells , 1971, Science.

[41]  N. Mitchison,et al.  Induction of immunological paralysis in two zones of dosage , 1964, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[42]  D. Dresser.  Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen. , 1962, Immunology.